DG Comp official: invisible hand isn’t working in pharma

Pharmaceutical investment incentives are better fueled by longer patent periods than by governments allowing drugmakers to block entry or charge excessive prices, a director at the European Commission’s Directorate-General for Competition has said.

Get unlimited access to all Global Competition Review content